A pediatric phase I study of the Wee1 inhibitor adavosertib plus irinotecan in children with relapsed solid and CNS tumors identified a recommended phase II dose (RP2D) and included two patients with NB, one of whom had stable disease (SD) (Table 1) [74]. The gene discussed is WEE1; the disease is neuroblastoma.